Breast hyperplasia
Fibrocystic breast disease is the most common breast disease in women, and its incidence ranks first among breast diseases. In recent years, the incidence of the disease has been increasing year by year, and the age of onset is getting younger and younger. Fibrocystic breast disease is the physiological proliferation and incomplete restoration of normal breast lobules, and the normal structure of the breast is disordered. It is a pathological hyperplasia. It is neither an inflammatory nor a tumor disease. It is more common in women aged 30-50, with the peak incidence at 35-40 years old.
-
Site of disease:
breast -
Infectious :
Not contagious -
Frequent population:
Women aged 30-50 -
Related symptoms:
Breast pain nodule cyst premenstrual breast pain axillary pain -
Concurrent disease:
Related Drugs
Breast core internal solution
Manufacturer:
Shandong Yuecaotang Pharmaceutical Co., Ltd.
Breast core internal solution
Manufacturer:
Henan Taloph Pharmaceutical Stock Co., Ltd.
Breast core internal solution
Manufacturer:
Henan Taloph Pharmaceutical Stock Co., Ltd.
Breast core internal solution
Manufacturer:
Tong Ren Tang Technologies Co., Ltd.
Breast core internal solution
Manufacturer:
Shaanxi Hualong Pharmaceutical Co., Ltd.
Breast core internal solution
Manufacturer:
Sinopharm Zhijun (SHENZHEN) Pingshan Pharmaceutical Co., Ltd.
Breast core internal solution
Manufacturer:
Sichuan Xinlu Pharmaceutical Co., Ltd.
Breast core internal solution
Manufacturer:
Jilin Beiqi Technology Pharmaceutical Co., Ltd.
Tamoxifen Citrate Tablets
Indication: 1. Treat recurrent and metastatic breast cancer in women; 2. Used as an adjuvant treatment for metastatic breast cancer after surgery to prevent recurrence.
Manufacturer:
Shanghai Fudan Fuhua Pharmaceutical Co., Ltd.
Ru Zeng Ning Capsules
Manufacturer:
Liuhe Changlong Pharmaceutical Co., Ltd.
Related Ingredients
-
Tamoxifen citrate list
54965-24-1 -
Dehydroandrographolide list
134418-28-3